Growing Attention To Psychedelics For Pain, Physical and Neurological Conditions: mechanisms and recent conferences highlight expanded therapeutic uses

Psychedelics are gaining increased attention as potential treatments for chronic pain and other physical or neurological conditions, broadening interest beyond classic psychiatric use. The page connects this momentum to ongoing trials and mentions a range of conditions where psychedelic research is being explored, including fibromyalgia, phantom-limb pain, spinal cord injury pain, Lupus, peripheral neuropathy, CRPS, neuropathic pain, IBS, Lyme disease-related problems, Long-COVID, and Parkinson’s. It also summarizes multiple proposed mechanisms for pain reduction: structural neuroplasticity, non-opioid pain inhibition via the 5-HT2A receptor, anti-inflammatory effects, cortical reorganization, reopening critical periods through metaplasticity, and psychosocial reframing that can break pain-mood feedback loops. It then points to recent signals of growing field-wide focus, including MAPS Psychedelic Science 2025 panels and SXSW sessions on psilocybin for pain and neurological healing, plus an online Psychedelics and Pain Symposium scheduled for September 27 and 28, 2025 that brings together researchers, clinicians, patients, and advocates.